Acesion Pharma ApS is going after a new target in atrial fibrillation - SK channels. The NeuroSearch A/S spinout expects its small molecule inhibitors to have fewer side effects than marketed AF drugs.

Marketed drugs for AF include the generic amiodarone, Sanofi's Multaq dronedarone and Cardiome Pharma Corp.'s Brinavess vernakalant. Brinavess is approved only in Europe, while the others are available worldwide.